Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pelthos Therapeutics (PTHS) Enterprise Value (2024 - 2025)

Pelthos Therapeutics has reported Enterprise Value over the past 2 years, most recently at -$18.0 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$18.0 million for Q4 2025, down 3413.26% from a year ago — trailing twelve months through Dec 2025 was -$18.0 million (down 3413.26% YoY), and the annual figure for FY2025 was -$18.0 million, down 3413.26%.
  • Enterprise Value for Q4 2025 was -$18.0 million at Pelthos Therapeutics, down from -$14.3 million in the prior quarter.
  • Over the last five years, Enterprise Value for PTHS hit a ceiling of -$59172.0 in Q2 2025 and a floor of -$18.0 million in Q4 2025.